ZACKS RESEARCH

FUNDS

PORTFOLIO

BROKER RESEARCH

MARKETS

SCREENING

EDUCATION

SERVICES

Earnings

EPS Surprises

Mutual Funds

Options

My Account

Help

PeopleandPicks.com is Zacks' Community Website
Find great stocks and great stock pickers in our online community. It's social, it's profitable and it's Free! Join the fun at PeopleandPicks.com

Quote:

Search for Ticker

Free Membership

Search:

BVF: Biovail Corp - Full Company Report Enter Ticker:

Quote	Estimates	Charts	Company Reports	News	Financials

Full Company Report \| Estimates \| Brokerage Recommendations \| Comparison to Industry \| Insiders \| Brokerage Reports \| Zacks Equity Research \| Annual Report

BIOVAIL CORP (NYSE)
BVF	14.42	0.19	(1.34%)	Vol. 232,815	14:40 ET

Biovail Corporation is a specialty pharmaceutical company, engaged in the formulation, clinical testing, registration, manufacture and commercialization of pharmaceutical products utilizing advanced drug-delivery technologies. Biovail's position of leadership as an innovative developer of medicines is based on its use of advanced drug- delivery technologies that provide significant therapeutic advantages over existing formulations. The Company has a number of proprietary drug-delivery platforms that can be applied to existing in-market drugs to develop enhanced formulations that offer more consistent drug release, greater patient compliance and, potentially, superior efficacy and lower incidence of side effects.

General Information

BIOVAIL CORP

- -, - - Phone: - Fax: - Web: - Email: None

Industry	MED-DRUGS
Sector:	Medical

Fiscal Year End	December
Last Reported Quarter	09/30/09
Next EPS Date	02/25/2010

Price and Volume Information

Zacks Rank
Yesterday's Close	14.23
52 Week High	15.50
52 Week Low	7.88
Beta	0.76
20 Day Moving Average	1,666,488.25
Target Price Consensus	16.08

% Price Change
4 Week	4.33
12 Week	15.22
YTD	50.58

% Price Change Relative to S&P 500
4 Week	0.34
12 Week	4.01
YTD	24.71

Share Information
Shares Outstanding (millions)	158.23
Market Capitalization (millions)	2,251.64
Short Ratio	3.02
Last Split Date	10/16/2000

Dividend Information
Dividend Yield	2.53%
Annual Dividend	$0.36
Payout Ratio	0.26
Change in Payout Ratio	0.00
Last Dividend Payout / Amount	08/28/2009 / $0.09

EPS Information
Current Quarter EPS Consensus Estimate	0.41
Current Year EPS Consensus Estimate	1.30
Estimated Long-Term EPS Growth Rate	15.00
Next EPS Report Date	02/25/2010

Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell)	1.55
30 Days Ago	1.55
60 Days Ago	1.39
90 Days Ago	1.75

Fundamental Ratios

P/E
Current FY Estimate:	10.97
Trailing 12 Months:	10.09
PEG Ratio	0.73

EPS Growth
vs. Previous Year	-8.57%
vs. Previous Quarter	-5.88%

Sales Growth
vs. Previous Year	17.36%
vs. Previous Quarter:	9.81%

Price Ratios
Price/Book	1.74
Price/Cash Flow	6.60
Price / Sales	2.96

ROE
09/30/09	18.24
06/30/09	19.12
03/31/09	19.87

ROA
09/30/09	12.37
06/30/09	13.61
03/31/09	14.85

Current Ratio
09/30/09	1.14
06/30/09	1.13
03/31/09	2.03

Quick Ratio
09/30/09	0.80
06/30/09	0.81
03/31/09	1.77

Operating Margin
09/30/09	29.51
06/30/09	31.43
03/31/09	32.51

Net Margin
09/30/09	20.86
06/30/09	22.47
03/31/09	16.13

Pre-Tax Margin
09/30/09	20.86
06/30/09	22.47
03/31/09	16.13

Book Value
09/30/09	8.16
06/30/09	7.93
03/31/09	7.44

Inventory Turnover
09/30/09	3.00
06/30/09	2.99
03/31/09	2.90

Debt-to-Equity
09/30/09	0.00
06/30/09	0.00
03/31/09	0.00

Debt to Capital
09/30/09	0.00
06/30/09	0.00
03/31/09	0.00


About Zacks \| Advertise \| Media \| Careers \| Contact Us \| Help Disclaimer \| Privacy Policy \| Sitemap NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed. Copyright 2009 Zacks Investment Research